Navigation Links
China Medical Technologies Senior Management Purchased Company Shares

BEIJING, March 6 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that each of Mr. Xiaodong Wu, the Company's Chairman and Chief Executive Officer, Mr. Sam Tsang, the Company's Chief Financial Officer and Dr. Zhong Chen, the Company's Chief Technology Officer, purchased the Company's American Depositary Shares (''ADSs'') in the open market in the past two days.

Mr. Wu purchased 150,000 ADSs at an average price of US$13.07 per ADS. Mr. Tsang purchased 6,500 ADSs at an average price of US$13.15 per ADS. Dr. Chen purchased 5,000 ADSs at an average price of US$12.81 per ADS.

Mr. Wu has indicated to the Company that he may continue to purchase the Company's ADSs in the open market in the future in compliance with the Company's insider trading policy.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic (IVD) products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit .

    For more information, please contact:

     Winnie Yam
     Tel:   +86-10-6530-8833

SOURCE China Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Bio-Immunity Corporation - Rabies Vaccine Recall
2. China Medicine to Participate in 2009 Natural Products Expo West Trade Show
3. China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets
4. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
5. Dow AgroSciences, China National Rice Research Institute Announce Collaboration on Rice Research
6. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
7. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
8. China Biologic Products Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
9. China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan
10. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
11. Syngenta Enters Into Research Collaboration With Anhui Academy, China
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):